Adbry (tralokinumab-ldrm) is a prescription drug that’s used to treat atopic dermatitis (eczema). Adbry comes as a liquid solution that you inject under your skin. Adbry is used in adults and certain ...

LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s ability to drive clear or almost clear skin for up ...

If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry ™ (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic ...

Hoping to cut into the dominance of Dupixent, Leo Pharma of Denmark has gained FDA approval for Adbry (tralokinumab) as a treatment for moderate to severe atopic dermatitis. The injected antibody drug ...

Interim post-hoc efficacy analysis from ECZTEND, an open-label, 5-year extension trial, showed long-term improvements in extent and severity of atopic dermatitis and itch in a subgroup of adult ...

The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD. The Food and Drug Administration ...

The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...

Privately held Leo Pharma Inc. has worked its way through a complete response letter issued in April to see the FDA approve Adbry (tralokinumab-ldrm) for treating moderate to severe atopic dermatitis ...

Please provide your email address to receive an email when new articles are posted on . Full results of the long-term ECZTEND trial of Adbry for atopic dermatitis were announced at the Fall Clinical ...

“Today’s FDA approval of Adbry is a major milestone for LEO Pharma and for the millions of people living with moderate-to-severe atopic dermatitis who struggle to find a suitable treatment option for ...